View source for Alpha blocker

{{Short description|Class of pharmacological agents}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Distinguish|Alphablocks}}
{{Infobox drug class
| Name = Alpha blockers <br /> α-blockers
| Use = {{bull}}[[Hypertension]]<br />{{bull}}[[Vasoconstriction]]<br />{{bull}}[[Benign prostatic hyperplasia|BPH]]<br />{{bull}}[[Raynaud's Disease]]<br / >{{bull}}[[Pheochromocytoma]]<br />{{bull}}[[Congestive heart failure|CHF]]<br />{{bull}}[[Erectile Dysfunction]]
| Biological_target = [[Adrenergic receptor#.CE.B1 receptors|α-adrenoceptors]]
| Mechanism_of_action = {{bull}}[[Receptor antagonist]]<br />{{bull}}[[Inverse agonist]]<br />{{bull}}[[Neutral antagonist]]
| MeshID = 
| Drugs.com = 
}}[[File:Alpha blocker location.png|thumb|Specific locations and functions of the α receptors. ''Image from Basic and Clinical Pharmacology by Bertram Katzung, et al.''<ref>{{cite book|title=Basic and Clinical Pharmacology |url=https://archive.org/details/basicclinicalpha00katz |url-access=registration | vauthors = Katzung B |year=1987 |publisher=Appleton & Lange |isbn=9780838505533 }}</ref> |288x288px]]

'''Alpha blockers''', also known as '''α-blockers''' or '''α-adrenoreceptor antagonists''', are a class of  [[pharmacological agent]]s that act as [[neutral antagonist|antagonist]]s on [[Adrenergic receptor#.CE.B1 receptors|α-adrenergic receptor]]s ([[Adrenergic receptor|α-adrenoceptors]]).<ref name="Katzung_2013" />

Historically, alpha-blockers were used as a tool for pharmacologic research to develop a greater understanding of the autonomic nervous system. Using alpha blockers, scientists began characterizing arterial blood pressure and central vasomotor control in the autonomic nervous system.<ref>{{cite journal | vauthors = Bousquet P, Schwartz J | title = Alpha-adrenergic drugs. Pharmacological tools for the study of the central vasomotor control | journal = Biochemical Pharmacology | volume = 32 | issue = 9 | pages = 1459–1465 | date = May 1983 | pmid = 6134533 | doi = 10.1016/0006-2952(83)90466-5 }}</ref> Today, they can be used as clinical treatments for a limited number of diseases.<ref name="Katzung_2013">{{Cite book|title=Basic and Clinical Pharmacology| vauthors = Katzung B, Masters S |publisher=Lange|year=2013|isbn=978-0-07-176402-5}}</ref>

Alpha blockers can treat a small range of diseases such as [[hypertension]], [[Raynaud syndrome|Raynaud's disease]], [[benign prostatic hyperplasia]] (BPH) and [[erectile dysfunction]].<ref name="Katzung_2013" /> Generally speaking, these treatments function by binding an α-blocker to α receptors in the arteries and smooth muscle. Ultimately, depending on the type of alpha receptor, this relaxes the smooth muscle or blood vessels, which increases fluid flow in these entities.<ref name="Katzung_2013" />

== Classification ==
[[File:GPCR and itegrin signaling diagram.png|class=skin-invert-image|400px|thumb|Schematic of G protein coupled receptor signaling, representing Gi GPCR signaling, Gs GPCR signaling, and Gq GPCR signaling.]]

* [[Alpha-1 blocker|α<sub>1</sub>-blockers]] act on [[alpha-1 adrenergic receptor|α<sub>1</sub>-adrenoceptors]]
* [[Alpha-2 blocker|α<sub>2</sub>-blockers]] act on [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenoceptors]]
When the term "alpha blocker" is used without further qualification, it can refer to an [[Alpha-1 blocker|α<sub>1</sub>]] blocker, an [[Alpha-2 blocker|α<sub>2</sub>]] blocker, a nonselective blocker (both [[Alpha-1 blocker|α<sub>1</sub>]] and [[Alpha-2 blocker|α<sub>2</sub>]] activity), or an [[Alpha-1 blocker|α]] blocker with some β activity.<ref name="Katzung_2013" /> However, the most common type of alpha blocker is usually an [[Alpha-1 blocker|α]]<sub>1</sub> blocker.

Non-selective α-adrenergic receptor antagonists include:
* [[Phenoxybenzamine]]
* [[Phentolamine]]
* [[Tolazoline]]
* [[Trazodone]]

Selective α<sub>1</sub>-adrenergic receptor antagonists include:
* [[Alfuzosin]]<ref>{{cite journal | vauthors = McKeage K, Plosker GL | title = Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia | journal = Drugs | volume = 62 | issue = 4 | pages = 633–653 | date = 2002-03-01 | pmid = 11893233 | doi = 10.2165/00003495-200262040-00009 | s2cid = 250307179 }}</ref>
* [[Doxazosin]]<ref name="Nash_1990">{{cite journal | vauthors = Nash DT | title = Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism | journal = Clinical Cardiology | volume = 13 | issue = 11 | pages = 764–772 | date = November 1990 | pmid = 1980236 | doi = 10.1002/clc.4960131104 | s2cid = 24619863 | doi-access = free }}</ref>
* [[Prazosin]] ([[inverse agonist]])<ref name="Green_2014">{{cite journal | vauthors = Green B | title = Prazosin in the treatment of PTSD | journal = Journal of Psychiatric Practice | volume = 20 | issue = 4 | pages = 253–259 | date = July 2014 | pmid = 25036580 | doi = 10.1097/01.pra.0000452561.98286.1e | s2cid = 40069887 }}</ref>
* [[Tamsulosin]]<ref>{{Cite web|date=|title=Tamsulosin Monograph for Professionals|url=https://www.drugs.com/monograph/tamsulosin.html|url-status=live|archive-url=https://web.archive.org/web/20210120045327/https://www.drugs.com/monograph/tamsulosin.html |archive-date=2021-01-20 |access-date=29 January 2021|website=[[Drugs.com]]}}</ref>
* [[Terazosin]]<ref name="Lepor_1991">{{cite journal | vauthors = Lepor H, Henry D, Laddu AR | title = The efficacy and safety of terazosin for the treatment of symptomatic BPH | journal = The Prostate | volume = 18 | issue = 4 | pages = 345–355 | date = 1991-01-01 | pmid = 1711689 | doi = 10.1002/pros.2990180408 | s2cid = 37160206 }}</ref>
* [[Silodosin]]<ref>{{Cite journal| vauthors = Michel MC |title=The Pharmacological Profile of the α1A-Adrenoceptor Antagonist Silodosin|journal=European Urology Supplements|volume=9|issue=4|pages=486–490|doi=10.1016/j.eursup.2010.03.006|year=2010}}</ref>

Selective α<sub>2</sub>-adrenergic receptor antagonists include:
* [[Atipamezole]]
* [[Idazoxan]]
* [[Mirtazapine]]
* [[Yohimbine]]

Finally, the agents [[carvedilol]] and [[labetalol]] are both α and [[beta blocker|β-blockers]].

Below are some of the most common drugs used in the clinic.

{| class="wikitable"
!Drug Name
!Common Brands
!Structure
!Mechanism of Action
!Effects
!Clinical Applications
!Toxicity
|-
|[[Phenoxybenzamine]]
|Dibenzyline
|[[File:Phenoxybenzamine.svg|class=skin-invert-image|200px]]
|Nonselective covalent binding to α<sub>1</sub> and α<sub>2</sub> receptors.

Irreversibly binds.<ref name="Katzung_2013" /><ref name="Mycek_1997">{{Cite book|title=Pharmacology| vauthors = Mycek MJ, Harvey RA, Champe PC |date=1997|publisher=Lippincott-Raven|isbn=978-0397515677|edition=2nd|location=Philadelphia|oclc=34905985}}</ref>
|Lowers blood pressure by decreasing peripheral resistance.

Blocks alpha induced vasconstriction.<ref name="Katzung_2013" />
|
* [[Pheochromocytoma]]
* Excess [[catecholamine]] release <ref name="Katzung_2013" />
|
* Orthostatic hypotension
* [[Tachycardia]]
* Nausea 
* Vomiting <ref name="Katzung_2013" /><ref name="Mycek_1997" /> 
|-
|[[Phentolamine]]
|Regitine
|[[File:Phentolamine Structural Formulae.svg|class=skin-invert-image|200px]]
|Competitive blocking of α<sub>1</sub> and α<sub>2</sub> receptors.

4 hours of action after initial administration.<ref name="Katzung_2013" /><ref name="Mycek_1997" />
|Reversal of epinephrine induced effects.

Lowers blood pressure by decreasing peripheral resistance.<ref name="Katzung_2013" /><ref name="Mycek_1997" />
|
* [[Pheochromocytoma]]<ref name="Katzung_2013" />
|
* Reflex cardiac stimulation
* Tachycardia
* Arrhythmia 
* Anginal pain <ref name="Mycek_1997" />
|-
|[[Prazosin]]
|Minipress
|[[File:Prazosin.svg|class=skin-invert-image|200px]]
|Inverse agonist of α<sub>1</sub>  receptor.<ref name="Mycek_1997" />
|Lowers blood pressure.<ref name="Katzung_2013" />
|
* [[Hypertension]]
* [[Benign prostatic hyperplasia]] (BPH)
* [[Posttraumatic stress disorder]] (PTSD)<ref name="Katzung_2013" /><ref name="Green_2014" /><ref name="Mycek_1997" />
|
* First dose effect
* Orthostatic hypotension
* Nasal congestion
* Dizziness
* Lack of energy
* Headache
* Drowsiness <ref name="Katzung_2013" /><ref name="Mycek_1997" />
|-
|[[Doxazosin]]
|Cardura
Cardura XL
|[[File:Doxazosin.svg|class=skin-invert-image|200px]]
|Competitive blocking of α<sub>1</sub>  receptor.<ref name="Mycek_1997" />
|Lowers blood pressure.<ref name="Katzung_2013" />
|
* [[Hypertension]]
* Benign prostatic hyperplasia<ref name="Nash_1990" />
|
* First dose effect
* Orthostatic hypotension
* Nasal congestion
* Dizziness
* Lack of energy
* Headache
* Drowsiness <ref name="Katzung_2013" /><ref name="Mycek_1997" />
|-
|[[Terazosin]]
|Hytrin
|[[File:Terazosin.svg|class=skin-invert-image|200px]]
|Competitive blocking of α<sub>1</sub>  receptor.<ref name="Mycek_1997" />
|Lowers blood pressure.<ref name="Katzung_2013" />
|
* [[Hypertension]]
* [[Benign prostatic hyperplasia|Benign prostatic hyperplasia (BPH)]]<ref name="Lepor_1991" />
|
* First dose effect
* Orthostatic hypotension
* Nasal congestion
* Dizziness
* Lack of energy
* Headache
* Drowsiness <ref name="Katzung_2013" /><ref name="Mycek_1997" />
|-
|[[Tamsulosin]]
|Flomax
|[[File:Tamsulosin Structure.svg|class=skin-invert-image|200px]]
|A blocker that has slight selectivity for α<sub>1</sub> receptors.<ref name="Katzung_2013" />
|Relaxation of prostatic smooth muscle.<ref name="Katzung_2013" />
|
* [[Benign prostatic hyperplasia]]<ref name="Katzung_2013" /><ref>{{cite journal | vauthors = Narayan P, Tunuguntla HS | title = Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia | journal = Reviews in Urology | volume = 7 | issue = Suppl 4 | pages = S42–S48 | date = 2005 | pmid = 16986054 | pmc = 1477608 }}</ref>
|
* Orthostatic hypotension <ref name="Katzung_2013" />
|-
|[[Yohimbine]]
|Yocon
|[[File:Yohimbine structure.svg|class=skin-invert-image|200px]]
|Blocks α<sub>2</sub> receptor, and increases norepinephrine release, thus increasing CNS activity.<ref name="Katzung_2013" />
|Raises blood pressure and heart rate.<ref name="Katzung_2013" />
|
* [[Sexual stimulation]]
* [[Erectile dysfunction|Male erectile dysfunction]]
* [[Hypotension]]<ref name="Katzung_2013" />
|
* May cause anxiety<ref>{{cite journal | vauthors = Charney DS, Woods SW, Goodman WK, Heninger GR | title = Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks | journal = The American Journal of Psychiatry | volume = 144 | issue = 8 | pages = 1030–1036 | date = August 1987 | pmid = 3037926 | doi = 10.1176/ajp.144.8.1030 }}</ref>
* Central Nervous System stimulation
|-
|[[Labetalol]]
|Trandate
|[[File:Labetalol.svg|class=skin-invert-image|200px]]
|Blocks some α<sub>1</sub> receptor activity, but binds more strongly to β receptors.<ref name="Katzung_2013" />
|Lowers blood pressure, increases heart rate slightly.<ref name="Katzung_2013" />
|
* [[Hypertension]]<ref name="Katzung_2013" /><ref>{{cite journal | vauthors = Richards DA | title = Pharmacological effects of labetalol in man | journal = British Journal of Clinical Pharmacology | volume = 3 | issue = 4 Suppl 3 | pages = 721–723 | date = August 1976 | pmid = 10949 }}</ref>
|
* May cause tachycardia <ref name="Katzung_2013" />
|-
|[[Carvedilol]]
|Coreg
Coreg CR
|[[File:Carvedilol.svg|class=skin-invert-image|200px]]
|Blocks some α<sub>1</sub> receptor activity, but binds more strongly to β receptors.<ref name="Katzung_2013" />
|Can interfere with noradrenergic mechanisms.<ref name="Katzung_2013" />
|
* [[Congestive heart failure]](CHF)<ref name="Katzung_2013" /><ref>{{cite journal | vauthors = Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA | title = Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group | journal = Journal of Cardiac Failure | volume = 3 | issue = 3 | pages = 173–179 | date = September 1997 | pmid = 9330125 | doi = 10.1016/s1071-9164(97)90013-0 | doi-access = free }}</ref>
|
* Fatigue <ref name="Katzung_2013" />
|}

==  Medical uses ==
While there are limited clinical α-blocker uses, in which most α-blockers are used for [[hypertension]] or [[benign prostatic hyperplasia]], α-blockers can be used to treat a few other diseases, such as [[Raynaud's disease]], [[congestive heart failure]] (CHF), [[pheochromocytoma]], and [[erectile dysfunction]].<ref>{{cite journal | vauthors = Roehrborn CG, Schwinn DA | title = Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia | journal = The Journal of Urology | volume = 171 | issue = 3 | pages = 1029–1035 | date = March 2004 | pmid = 14767264 | doi = 10.1097/01.ju.0000097026.43866.cc }}</ref><ref>{{cite journal | vauthors = Messerli FH | title = Doxazosin and congestive heart failure | journal = Journal of the American College of Cardiology | volume = 38 | issue = 5 | pages = 1295–1296 | date = November 2001 | pmid = 11691497 | doi = 10.1016/s0735-1097(01)01534-0 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Ernst E, Pittler MH | title = Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials | journal = The Journal of Urology | volume = 159 | issue = 2 | pages = 433–436 | date = February 1998 | pmid = 9649257 | doi = 10.1016/s0022-5347(01)63942-9 }}</ref>

Furthermore, α-blockers can occasionally be used to treat anxiety and panic disorders, such as [[posttraumatic stress disorder]] (PTSD) induced [[nightmare]]s.<ref name="Green_2014" /> Studies have also had great medical interest in testing alpha blockers, specifically α<sub>2</sub> blockers, to treat [[Diabetes mellitus type 2|type II diabetes]] and [[Depression (mood)|psychiatric depression]].<ref name="Katzung_2013" />

=== Hypertension ===
[[Hypertension]] is due to an increase in vascular resistance and vasoconstriction. Using α<sub>1</sub> selective antagonists, such as [[prazosin]], has been efficacious in treating mild to moderate hypertension. This is because they can decrease vascular resistance and decrease pressure.<ref name="Katzung_2013" /><ref>{{cite journal | vauthors = Laurent S | title = Antihypertensive drugs | journal = Pharmacological Research | volume = 124 | pages = 116–125 | date = October 2017 | pmid = 28780421 | doi = 10.1016/j.phrs.2017.07.026 | s2cid = 251991 }}</ref> However, while these drugs are generally well tolerated, they have the potential to produce side effects such as orthostatic hypotension and dizziness.<ref name="Katzung_2013" /> However, unlike other treatments for hypertension such as [[ACE inhibitors]], [[Angiotensin receptor blockers|ARBs]], [[calcium channel blockers]], [[thiazide diuretics]] or [[beta blockers]], alpha blockers have not demonstrated the same mortality and morbidity benefits, and are therefore not generally used as first or even second line agents.

Another treatment for hypertension is using drugs that have both α<sub>1</sub> blocking activity, as well as nonselective β activity, such as [[Labetalol]] or [[carvedilol]].<ref name="Brogden_1978">{{cite journal | vauthors = Brogden RN, Heel RC, Speight TM, Avery GS | title = Labetalol: a review of its pharmacology and therapeutic use in hypertension | journal = Drugs | volume = 15 | issue = 4 | pages = 251–270 | date = April 1978 | pmid = 25757 | doi = 10.2165/00003495-197815040-00002 | s2cid = 42161040 }}</ref> In low doses, labetalol and carvedilol can decrease the peripheral resistance and block the effects of isoprenaline to reduce hypertensive symptoms.<ref name="Brogden_1978" />

=== Pheochromocytoma ===
[[File:Pheochromocytoma.jpg|thumb|An image of a patient with pheochromocytoma. In patients with this disease, a catecholamine-secreting tumor is formed, and causes excess CNS stimulation, such as excess sweating and tachycardia. Nonselective alpha blockers, such as phenoxybenzamine or phentolamine, can be used to mitigate this disease.]]
[[Pheochromocytoma]] is a disease in which a catecholamine secreting tumor develops.<ref name="Katzung_2013" /><ref name="Bravo_2002">{{cite journal | vauthors = Bravo EL | title = Pheochromocytoma: an approach to antihypertensive management | journal = Annals of the New York Academy of Sciences | volume = 970 | issue = 1 | pages = 1–10 | date = September 2002 | pmid = 12381537 | doi = 10.1111/j.1749-6632.2002.tb04408.x | s2cid = 222084372 | bibcode = 2002NYASA.970....1B }}</ref> Specifically, norepinephrine and epinephrine are secreted by these tumors, either continuously or intermittently.<ref name="Das_2017"/> The excess release of these catecholamines increases central nervous system stimulation, thus causing blood vessels to increase in vascular resistance, and ultimately giving rise to hypertension.<ref name="Bravo_2002" /> In addition, patients with these rare tumors are often subject to headaches, heart palpitations, and increased sweating.<ref name="Katzung_2013" />

[[Phenoxybenzamine]], a nonselective α<sub>1</sub> and α<sub>2</sub> blocker, has been used to treat pheochromocytoma.<ref name="Das_2017">{{Cite journal| vauthors = Das S, Kumar P, Kiran U, Airan B |date= January 2017 |title=Alpha blockers: A relook at phenoxybenzamine|journal=Journal of the Practice of Cardiovascular Sciences|language=en|volume=3|issue=1|pages=11|doi=10.4103/jpcs.jpcs_42_16|doi-access=free}}</ref> This drug blocks the activity of epinephrine and norepinephrine by antagonizing the alpha receptors, thus decreasing vascular resistance, increasing vasodilation, and decreasing blood pressure overall.<ref name="Das_2017" />

=== Congestive heart failure ===
Blockers that have both the ability to block both α and β receptors, such as [[carvedilol]], [[bucindolol]], and [[labetalol]], have the ability to mitigate the symptoms in [[congestive heart failure]].<ref name="Bristow_2000">{{cite journal | vauthors = Bristow MR | title = beta-adrenergic receptor blockade in chronic heart failure | journal = Circulation | volume = 101 | issue = 5 | pages = 558–569 | date = February 2000 | pmid = 10662755 | doi = 10.1161/01.CIR.101.5.558 | doi-access = free }}</ref> By binding to both the α and β receptors, these drugs can decrease the cardiac output and stimulate the dilation of blood vessels to promote a reduction in blood pressure.<ref name="Bristow_2000" />

=== Erectile dysfunction ===
[[Yohimbine]], an α<sub>2</sub> blocker derived from the bark of the ''[[Pausinystalia johimbe]]'' tree, has been tested to increase libido and treat erectile dysfunction. The proposed mechanism for yohimbine is blockade of the adrenergic receptors that are associated with [[neurotransmitters]] inhibition, including [[dopamine]] and [[nitric oxide]], and thus aiding with penile erection and libido.<ref name="Lue_2000" /> By doing so, they can alter the blood flow in the penis to aid in achieving an erection. However, some side effects can occur, such as [[Palpitations|palpitation]], [[tremor]], [[Hypertension|elevated blood pressure]], and [[anxiety]].<ref name="Lue_2000">{{cite journal | vauthors = Lue TF | title = Erectile dysfunction | language = EN | journal = The New England Journal of Medicine | volume = 342 | issue = 24 | pages = 1802–1813 | date = June 2000 | pmid = 10853004 | doi = 10.1056/nejm200006153422407 }}</ref>
[[Yohimbe bark]] contains both α<sub>1</sub> and α<sub>2</sub> [[adrenergic receptors]] blocking [[alkaloids]].

[[Phentolamine]], a non-selective alpha blocker, has also been tested to treat erectile dysfunction. By reducing vasoconstriction in the penis, there appears to be increased blood flow that aids in penile erection. Side effects associated with phentolamine include headache, flushing, and nasal congestion.<ref name="Lue_2000" />
[[File:BPH.png|thumb|236x236px|Benign prostate hyperplasia, a disease in which urinary retention becomes an issue. Alpha-1 blockers can be used, but it can result in side effects such as increased urination and retrograde ejaculation.]]

[[Phenoxybenzamine]], a non-competitive α<sub>1</sub> and α<sub>2</sub> blocker was used by Dr. [[Giles Brindley]] in the first intracavernosal pharmacotherapy for erectile dysfunction.<ref>{{cite book | chapter = A Description of the Pioneering Work That Led to the First Approved Agents for ED: Giles Brindley, the Needle, and the Penis (Phenoxybenzamine) |date=2007 | title =Key Clinical Trials in Erectile Dysfunction |pages=4–7 | veditors = Carson CC |place=London |publisher=Springer |language=en |doi=10.1007/978-1-84628-428-1_2 |isbn=978-1-84628-428-1}}</ref>

=== Benign prostatic hyperplasia ===
In [[benign prostatic hyperplasia]] (BPH), men experience urinary obstruction and are unable to urinate, thus leading to urinary retention.<ref name="Katzung_2013" /> α<sub>1</sub> specific blockers have been used to relax the smooth muscle in the bladder and enlarged prostate.<ref name="Chapple_1996">{{cite journal | vauthors = Chapple CR | title = Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience | journal = European Urology | volume = 29 | issue = 2 | pages = 129–144 | date = January 1996 | pmid = 8647139 }}</ref> [[Prazosin]], [[doxazosin]], and [[terazosin]] have been particularly useful for patients with BPH, especially in patients with hypertension.<ref name="Katzung_2013" /> In such patients, these drugs can treat both conditions at the same time.<ref name="Katzung_2013" /> In patients without hypertension, [[tamsulosin]] can be used, as it has the ability to relax the bladder and prostate smooth muscle without causing major changes in blood pressure.<ref name="Chapple_1996" />

=== Raynaud's disease ===
[[File:Raynaud's Syndrome.jpg|thumb|Patients with Raynaud's syndrome experience cut off blood flow from the fingers causing a large decrease in oxygen, which leads to the discoloration of the fingers. Using alpha blockers aids in restoring blood flow and treating the syndrome by stimulating the dilation of blood vessels. |283x283px]]
Both α<sub>1</sub> blockers and α<sub>2</sub> blockers have been examined to treat [[Raynaud syndrome|Raynaud's disease]]. Although α<sub>1</sub> blockers, such as [[prazosin]], have appeared to give slight improvement for the sclerotic symptoms of Raynaud's disease, there are many side effects that occur while taking this drug. Conversely, α<sub>2</sub> blockers, such as yohimbine, appear to provide significant improvement of the sclerotic symptoms in Raynaud's Disease without excessive side effects.<ref>{{cite journal | vauthors = Bakst R, Merola JF, Franks AG, Sanchez M | title = Raynaud's phenomenon: pathogenesis and management | journal = Journal of the American Academy of Dermatology | volume = 59 | issue = 4 | pages = 633–653 | date = October 2008 | pmid = 18656283 | doi = 10.1016/j.jaad.2008.06.004 }}</ref>

=== Post traumatic stress disorder ===
Patients with [[posttraumatic stress disorder]] (PTSD) have often continued to be symptomatic despite being treated with PTSD-specific drugs.<ref name="Koola_2014">{{cite journal | vauthors = Koola MM, Varghese SP, Fawcett JA | title = High-dose prazosin for the treatment of post-traumatic stress disorder | journal = Therapeutic Advances in Psychopharmacology | volume = 4 | issue = 1 | pages = 43–47 | date = February 2014 | pmid = 24490030 | pmc = 3896131 | doi = 10.1177/2045125313500982 }}</ref> In addition, PTSD patients often have debilitating nightmares that continue, despite their treatments.<ref name="Koola_2014" /> High doses of the α<sub>1</sub> blocker, [[prazosin]], have been efficacious in treating patients with PTSD induced nightmares due to its ability to block the effects of norepinephrine.<ref name="Koola_2014" />

Adverse effects of prazosin to treat PTSD nightmares include [[dizziness]], [[First-dose phenomenon|first dose effect]] (a sudden loss of consciousness), [[weakness]], [[nausea]], and [[Fatigue (medical)|fatigue]].<ref name="Koola_2014" />

== Adverse effects ==
Although alpha blockers have the ability to reduce some disease pathology, there are some side effects that come with these alpha blockers.<ref name="Alpha Adrenergic Blockers" /> However, because there are several structural compositions that make each alpha blocker different, the side effects are different for each drug. Side effects that arise when taking alpha blockers can include the [[First-dose phenomenon|first dose effect]],  cardiovascular side effects, genitourinary side effects, as well as other side effects.<ref name="Alpha Adrenergic Blockers">{{cite book|title=Pharmacology Made Easy| vauthors = Manning L, Rayfield S |publisher=ICAN|location=Bossier City, LA|page=38}}</ref>

=== First dose effect ===
One of the most common side effects with alpha blockers is the [[first dose effect]].<ref name="Hodsman_1983">{{cite journal | vauthors = Hodsman GP, Isles CG, Murray GD, Usherwood TP, Webb DJ, Robertson JI | title = Factors related to first dose hypotensive effect of captopril: prediction and treatment | journal = British Medical Journal | volume = 286 | issue = 6368 | pages = 832–834 | date = March 1983 | pmid = 6403103 | pmc = 1547159 | doi = 10.1136/bmj.286.6368.832 }}</ref> This is a phenomenon in which patients with hypertension take an alpha blocker for the first time, and suddenly experience an intense decrease in blood pressure. Ultimately, this gives rise to [[orthostatic hypotension]], [[dizziness]], and a sudden loss of consciousness due to the drastic drop in blood pressure.<ref name="Hodsman_1983" />

Alpha blockers that possess these side effects include [[prazosin]], [[doxazosin]], and [[terazosin]].<ref>{{Cite book| vauthors = Elliott HL |pages=1019–1025|language=en-us|doi=10.1016/b978-0-323-03961-1.50085-4|title = Comprehensive Hypertension|year = 2007|isbn = 9780323039611|chapter = Alpha Adrenoreceptor Antagonists}}</ref>

=== Cardiovascular side effects ===
There are some alpha blockers that can give rise to changes in the cardiovascular system, such as the induction of reflex tachycardia, orthostatic hypotension, or heart palpitations via alterations of the QT interval.<ref name="Alpha Adrenergic Blockers" /><ref>{{cite journal | vauthors = Lepor H, Lepor NE, Hill LA, Trohman RG | title = The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia | journal = Reviews in Urology | volume = 10 | issue = 2 | pages = 85–91 | date = Spring 2008 | pmid = 18660858 | pmc = 2483321 }}</ref> Alpha blockers that may have these side effects include [[yohimbine]], [[phenoxybenzamine]], and [[phentolamine]].<ref name="Katzung_2013" />

=== Genitourinary side effects ===
When alpha blockers are used to treat BPH, it causes vasodilation of blood vessels on the bladder and the prostate, thus increasing urination in general.<ref name="Lepor_2007">{{cite journal | vauthors = Lepor H | title = Alpha blockers for the treatment of benign prostatic hyperplasia | journal = Reviews in Urology | volume = 9 | issue = 4 | pages = 181–190 | date = Fall 2007 | pmid = 18231614 | pmc = 2213889 }}</ref> However, these alpha blockers can produce the exact opposite side effect, in which [[edema]], or abnormal fluid retention, occurs.<ref name="Prescriber_2011">{{Cite journal|date=July 2011|title=Alpha-blockers: their properties and use in hypertension|journal=Prescriber|volume=22|issue=13–14|pages=38–39|doi=10.1002/psb.779|doi-access=free}}</ref>

In addition, due to the relaxation of the prostate smooth muscle, another side effect that arises in men being treated for BPH is impotence, as well as the inability to ejaculate.<ref name="Lepor_2007" /><ref name="Debruyne_2000">{{cite journal | vauthors = Debruyne FM | title = Alpha blockers: are all created equal? | journal = Urology | volume = 56 | issue = 5 Suppl 1 | pages = 20–22 | date = November 2000 | pmid = 11074198 | doi = 10.1016/s0090-4295(00)00744-5 }}</ref> However, if any ejaculation activity does occur, oftentimes, it results in a phenomenon called [[retrograde ejaculation]], in which semen flows into the urinary bladder instead of exiting through the urethra.<ref name="Debruyne_2000" />

Drugs that may produce such side effects include [[prazosin]], [[terazosin]], [[tamsulosin]], and [[doxazosin]].<ref name="Debruyne_2000" />

=== Other side effects ===
Finally, there are other general side effects that can be caused by most alpha blockers (however, more frequently in alpha-1 blockers). Such side effects include [[dizziness]], [[drowsiness]], [[weakness]], [[fatigue (medical)|fatigue]], psychiatric [[Depression (mood)|depression]], and [[Xerostomia|dry mouth]].<ref name="Alpha Adrenergic Blockers" /><ref name="Debruyne_2000" />

Priapism, an unwanted, painful long term erection not brought on by sexual arousal and lasting several hours has been associated with alpha blocker use. While this is extremely rare, particularly with tamsulosin, it can cause permanent impotence if not treated in a hospital setting. Male patients should be made aware of this as it can result from a single dose or develop over time.

== Contraindications ==
There is only one compelling indication for alpha blockers, which is for [[benign prostatic hyperplasia]].<ref name="Prescriber_2011" /> Patients who need alpha blockers for BPH, but have a history of [[hypotension]] or [[Heart failure|postural heart failure]], should use these drugs with caution, as it may result in an even greater decrease in blood pressure or make heart failure even worse.<ref name="British Hypertension Society" /><ref name="cvpharmacology.com" /> The most compelling [[contraindication]] is [[urinary incontinence]] and overall fluid retention.<ref name="British Hypertension Society">{{Cite web|url=http://www.bhsoc.org/pdfs/therapeutics/Alpha-Adrenoceptor%20Antagonists%20(Alpha-Blockers).pdf|title=Alpha-Adrenoceptor Antagonists (Alpha-Blockers)|website=British Hypertension Society|archive-url=https://web.archive.org/web/20170829020552/http://www.bhsoc.org/pdfs/therapeutics/Alpha-Adrenoceptor%20Antagonists%20(Alpha-Blockers).pdf|archive-date=2017-08-29|url-status=dead}}</ref><ref name="cvpharmacology.com">{{Cite web|url=http://cvpharmacology.com/vasodilator/alpha|title=CV Pharmacology {{!}} Alpha-Adrenoceptor Antagonists (Alpha-Blockers)|website=cvpharmacology.com|access-date=2017-11-15}}</ref> To combat such fluid retention, patients can take a diuretic in combination with the alpha-blocker.<ref name="cvpharmacology.com" />

In the absence of compelling indications or contraindications, patients should take alpha blockers as a [[Step therapy|step 4 therapy]] to reduce blood pressure, but only if the use of ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, or thazide diuretics (in full dose or in combinations) have not been efficacious.<ref name="Prescriber_2011" /><ref name="British Hypertension Society" /><ref name="cvpharmacology.com" />

== Drug interactions ==
As with any drug, there are drug interactions that can occur with alpha blockers. For instance, alpha blockers that are used for the reduction of blood pressure, such as [[phenoxybenzamine]] or [[phentolamine]] can have synergy with other drugs that affect smooth muscle, blood vessels, or drugs used for [[erectile dysfunction]] (i.e. [[sildenafil]], [[tamsulosin]], etc.). This stimulates exaggerated [[hypotension]].<ref name="Katzung_2013" />

Alternative alpha blockers, such as [[prazosin]], [[tamsulosin]], [[doxazosin]], or [[terazosin]] can have adverse interactions with [[beta blocker]]s, [[erectile dysfunction]] drugs, [[anxiolytic]]s, and [[antihistamine]]s.<ref name="Katzung_2013" /> Again, these interactions can cause dangerous [[hypotension]]. Furthermore, in rare cases, drug interactions can cause irregular, rapid heartbeats or an increase blood pressure.<ref name="Katzung_2013" />

[[Yohimbine]] can interact with [[stimulant]]s, [[hypertension]] drugs, [[naloxone]], and [[clonidine]]. Interactions with such drugs can cause either an unintended increase in blood pressure or potentiate an increase in blood pressure.<ref name="Katzung_2013" />

Finally, in drugs with both alpha and beta blocking properties, such as [[carvedilol]] and [[labetalol]], interactions with other alpha or beta blockers can exaggerate a decrease in blood pressure.<ref name="Katzung_2013" /> Conversely, there are also drug interactions with carvedilol or labetalol in which blood pressure is increased unintentionally (such as with cough and cold medications).<ref name="Katzung_2013" /> Finally, there may also be some alpha/beta blocker drug interactions that can worsen previous heart failure.<ref name="Katzung_2013" />

== Mechanism of action ==
Alpha blockers work by blocking the effect of nerves in the sympathetic nervous system. This is done by binding to the alpha receptors in smooth muscle or blood vessels.<ref name="Knott_2015">{{Cite web|url=https://patient.info/health/alpha-blockers|title=Alpha-blockers| vauthors = Knott L |date=2015-06-27|website=Patient}}</ref> α-blockers can bind both reversibly and irreversibly.<ref name="Katzung_2013" />

There are several α receptors throughout the body where these drugs can bind. Specifically, α<sub>1</sub> receptors can be found in most vascular smooth muscle, the pupillary dilator muscle, the heart, the prostate, and pilomotor smooth muscle.<ref name="Katzung_2013" /> On the other hand, α<sub>2</sub> receptors can be found in platelets, cholinergic nerve terminals, some vascular smooth muscle, postsynaptic CNS neurons, and fat cells.<ref name="Katzung_2013" />

The structure of α receptors is a classic [[G protein–coupled receptor]]s (GPCRs) consisting of 7 transmembrane domains, which form three intracellular loops and three extracellular loops.<ref name="Katzung_2013" /> These receptors couple to heterotrimeric G proteins composed of α, β, and γ subunits.<ref name="Katzung_2013" /> Although both of the α receptors are GPCRs, there are large differences in their mechanism of action. Specifically, [[Alpha-1 adrenergic receptor|α<sub>1</sub> receptors]] are characterized as G<sub>q</sub> GPCRs, signaling through [[Phospholipase C]] to increase [[Ip3 dag pathway|IP<sub>3</sub>]] and [[Ip3 dag pathway|DAG]], thus increasing the release of calcium. Meanwhile, [[Alpha-2 adrenergic receptor|α<sub>2</sub> receptors]] are labeled as G<sub>i</sub> GPCRs, which signal through [[adenylyl cyclase]] to decrease [[Cyclic adenosine monophosphate|cAMP]].<ref>{{cite journal | vauthors = Pierce KL, Premont RT, Lefkowitz RJ | title = Seven-transmembrane receptors | journal = Nature Reviews. Molecular Cell Biology | volume = 3 | issue = 9 | pages = 639–650 | date = September 2002 | pmid = 12209124 | doi = 10.1038/nrm908 | s2cid = 23659116 }}</ref>

Because the α<sub>1</sub> and α<sub>2</sub> receptors have different mechanisms of action, their antagonists also have different effects.<ref>{{cite journal | vauthors = Bylund DB | title = Subtypes of alpha 1- and alpha 2-adrenergic receptors | journal = FASEB Journal | volume = 6 | issue = 3 | pages = 832–839 | date = February 1992 | pmid = 1346768 | doi = 10.1096/fasebj.6.3.1346768 | s2cid = 83827013 | doi-access = free }}</ref> α<sub>1</sub> blockers can inhibit the release of [[Ip3 dag pathway|IP<sub>3</sub>]] and [[Ip3 dag pathway|DAG]] to decrease calcium release, thus, decreasing overall signaling. On the other hand, α<sub>2</sub> blockers prevent the reduction of cAMP, thus leading to an increase in overall signaling.
{| class="wikitable"
![[File:Alpha_1_Receptor_Signaling_Cascade.gif|thumb|433x433px|Alpha-1 Receptor signaling cascade and antagonist signaling cascade.]]
![[File:A2receptor.gif|thumb|427x427px|Alpha-2 receptor signaling cascade and antagonist signaling cascade. |center]]
|}

== See also ==
*[[Beta blocker]]
* [[Adrenergic receptor]]
* [[Adrenergic antagonist]]
* [[Sympathetic nervous system]]

== References ==
{{reflist}}

{{Receptor agonists and antagonists}}
{{Alpha blockers}}
{{Drugs used in benign prostatic hypertrophy}}

[[Category:Alpha blockers| ]]